Poolbeg Pharma (POLB) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Dec 2024 07:00 AM
RNS
Poolbeg presents POLB 001 data at 66th ASH Meeting
20 Nov 2024 07:00 AM
RNS
POLB 001 Patent Granted in United States
06 Nov 2024 07:00 AM
RNS
POLB 001 data to be presented at ASH
18 Sep 2024 07:00 AM
RNS
Interim results for the six months to 30 June 2024
27 Aug 2024 07:00 AM
RNS
H.C. Wainwright Global Investment Conference
12 Aug 2024 01:28 PM
RNS
Holding(s) in Company
26 Jul 2024 07:00 AM
RNS
Voluntary Delisting from OTCQB Market
10 Jul 2024 07:00 AM
RNS
Notification of Major Holdings
02 Jul 2024 07:00 AM
RNS
Change of Registered Address
17 Jun 2024 08:38 AM
RNS
Result of AGM
09 May 2024 07:00 AM
RNS
Annual Report & AGM Notice
01 May 2024 07:00 AM
RNS
Significant POLB 001 Patent Granted in USA
30 Apr 2024 07:02 AM
RNS
Appointment of Joint Broker
30 Apr 2024 07:01 AM
RNS
Option Agreement to Acquire Orphan Drug Candidate
30 Apr 2024 07:00 AM
RNS
Results for the year ended 31 December 2023
29 Apr 2024 07:00 AM
RNS
TR-1: Notification of major holdings
20 Mar 2024 07:00 AM
RNS
POLB 001 US Patent Update
22 Feb 2024 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2024 01:42 PM
RNS
Director Share Purchase
15 Feb 2024 07:00 AM
RNS
Board Role Change and Launch of EIP
12 Feb 2024 07:00 AM
RNS
Market Opportunity for POLB 001 for CRS
17 Jan 2024 07:00 AM
RNS
Further data shows POLB001 potential in cancer CRS
20 Dec 2023 07:00 AM
RNS
RSV AI Drug Candidate Analysis Update
11 Dec 2023 07:00 AM
RNS
POLB 001 Data Presented at ASH
30 Nov 2023 07:00 AM
RNS
Directorate Change
21 Nov 2023 07:00 AM
RNS
Immunomodulator II patent granted in Japan
16 Nov 2023 07:00 AM
RNS
POLB 001 LPS Trial Data to be Presented at IUIS
09 Nov 2023 07:00 AM
RNS
Former Amryt Pharma Leadership Team join Poolbeg
03 Nov 2023 07:05 AM
RNS
POLB001 Data to be Presented at ASH Annual Meeting
01 Nov 2023 07:00 AM
RNS
POLB 001 Oncology Programme Update Meeting
26 Oct 2023 07:00 AM
RNS
SAB Endorses Influenza Drug Targets
17 Oct 2023 07:00 AM
RNS
Poolbeg Partners with a Nasdaq-Listed Biopharma
29 Sep 2023 07:00 AM
RNS
Favourable Conclusion of Patent Opposition
20 Sep 2023 07:00 AM
RNS
Immunomodulator I Patent Portfolio Strengthened
19 Sep 2023 07:00 AM
RNS
Immunomodulator I Patent Opposition Withdrawal
13 Sep 2023 07:00 AM
RNS
Interim results for the six months to 30 June 2023
29 Jun 2023 07:00 AM
RNS
AI led programme identifies influenza drug targets
22 Jun 2023 07:00 AM
RNS
Oral Vaccine Programme Moves Forward
24 May 2023 07:00 AM
RNS
Board Appointment
11 May 2023 02:27 PM
RNS
Results of Annual General Meeting
12 Apr 2023 07:00 AM
RNS
Annual Report & AGM Notice
30 Mar 2023 07:00 AM
RNS
Results for the year ended 31 December 2022
10 Mar 2023 07:00 AM
RNS
Notification of Major Holdings
09 Mar 2023 03:51 PM
RNS
Notification of Major Holdings
08 Mar 2023 07:00 AM
RNS
POLB 001 patent portfolio strengthened
02 Mar 2023 11:05 AM
RNS
Second Price Monitoring Extn
02 Mar 2023 11:00 AM
RNS
Price Monitoring Extension
02 Mar 2023 07:00 AM
RNS
Positive Results POLB001 LPS Human Challenge Trial
16 Jan 2023 07:00 AM
RNS
Strategic expansion of POLB 001 into oncology
09 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn

Poolbeg Pharma is a biopharmaceutical company that develops and commercialises medicines for unmet medical needs, including rare and orphan diseases. Poolbeg Pharma focuses on developing medicines for areas of high unmet need, such as cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions like obesity. It is listed on the stock exchange under the ticker POLB.

POLB share price launched at 11p in 2021.

 

UK 100

Latest directors dealings